NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC

CompletedN/A

Sponsor: Pfizer

Conditions: Breast Cancer, Breast Carcinoma

Countries: Brazil

The objective of this study is to describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments as first line therapy, regardless of combination partner and labelled use in real world settings across Brazil.

Eligibility overview

Sex: FEMALE

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* HR+/HER2- breast cancer diagnosis with confirmed ABC/MBC
* Received palbociclib as a first line therapy
* No prior or current enrolment in an interventional clinical trial for ABC/MBC
* Have a potential follow-up period of 6 months following the index date (30 days after first palbociclib prescription: palbociclib with fulvestrant and/or palbociclib with letrozole/aromatase inhibitor).

Exclusion Criteria:

* Patients who were enrolled to receive fulvestrant but already received previous therapies

Locations (14)

Salvador, Estado de Bahia, Brazil
Salvador, Estado de Bahia, Brazil
Brasília, Federal District, Brazil
Brasília, Federal District, Brazil
Goiânia, Goiás, Brazil
Belo Horizonte, Minas Gerais, Brazil
Florianópolis, Brazil
Goiânia, Brazil
Recife, Brazil
Rio de Janeiro, Brazil
Rio de Janeiro, Brazil
Rio de Janeiro, Brazil
São Paulo, Brazil
São Paulo, Brazil